PRTC

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

Retrieved on: 
星期三, 五月 29, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Patient, Baker McKenzie, PRTC, Virtual, Therapy, Mental health, VR, LLP, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, and Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, announced the signing of a definitive merger agreement to form a diversified, leading digital health company.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, and Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, announced the signing of a definitive merger agreement to form a diversified, leading digital health company.
  • The full text of the announcement from Akili and Virtual Therapeutics is as follows:
    Kirkland, Wash., and Boston, Mass.– Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced the signing of a definitive merger agreement to form a diversified, leading digital health company.
  • Under the terms of the agreement, Akili shareholders will receive $0.4340 per share of common stock in cash.
  • Following completion of the transaction, the combined organization will operate as Virtual Therapeutics, a privately held company, with Akili operating as a wholly owned subsidiary.

PureTech to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Conference, Patient, PRTC, EDT, Multimedia

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th, 2024, at 10:00am EDT / 3:00pm BST.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th, 2024, at 10:00am EDT / 3:00pm BST.
  • A webcast of the presentation will be available at https://investors.puretechhealth.com .
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240523522284/en/
    PureTech to Present at the Jefferies Global Healthcare Conference (Graphic: Business Wire)

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

Retrieved on: 
星期二, 五月 21, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, Recurrence, Clostridioides difficile infection, Risk, Food, AGAF, Variometer, PRTC, CDI, FACG, Safety, Hospital, Death, Yale School of Medicine, Biologics license application, Clostridioides, BLA, Therapy, Pivotal, Quality of life, Infection, Pharmaceutical industry

The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration.

Key Points: 
  • The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration.
  • VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI).
  • “Initiation of the RESTORATiVE303 study represents a key clinical milestone for the VE303 program.
  • “CDI may recur in 25% or more of those affected, sometimes repeatedly, despite initially successful antibiotic treatment.

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

Retrieved on: 
星期一, 五月 20, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Health, Science, Oncology, Other Science, Book, Form, CREST, Internal Revenue Code, Indian stock exchange, Special dividend, Letter, Form W-9, Schedule, Tender offer, Security (finance), Shareholder, PRTC, IRS, ADS, Attention, Certification, Mass meeting, Common stock, Patient, Tax, Computershare, Pavilion, Tender, Appendix, Citibank, Form W-2, Microsite

The Tender Offer will be implemented on the basis of Jefferies International Limited (“Jefferies”) acquiring, as principal, the successfully tendered Ordinary Shares (including Ordinary Shares represented by ADSs) at the Tender Price.

Key Points: 
  • The Tender Offer will be implemented on the basis of Jefferies International Limited (“Jefferies”) acquiring, as principal, the successfully tendered Ordinary Shares (including Ordinary Shares represented by ADSs) at the Tender Price.
  • The Company intends to cancel the Ordinary Shares (including Ordinary Shares represented by ADSs) purchased by it pursuant to the Tender Offer.
  • Shareholders can decide whether they want to tender all, some or none of their Ordinary Shares or ADSs in the Tender Offer.
  • The Information Agent with respect to the Tender Offer for ADSs and Ordinary Shares in the United States is Georgeson LLC.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, Human, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, PRTC, Annual general meeting, Therapy, Somnolence, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • The most common treatment-emergent adverse event was somnolence (29% SPT-300 vs. 13% placebo), which was transient and mild or moderate.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
星期二, 五月 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, PRTC, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Multimedia, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Patient, Acquisition, Pleasure, MBA, Growth

View the full release here: https://www.businesswire.com/news/home/20240507753971/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507753971/en/
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments (Graphic: Business Wire)
    The appointments follow the recent launch of Seaport , PureTech’s newest Founded Entity, with a $100 million Series A financing round.
  • Following the Series A financing, PureTech holds equity ownership in Seaport of 61.5 percent on a diluted basis.
  • In addition, Michael Chen, Ph.D., Co-founder, was named Chief Scientific Officer, and Eric Green, MBA, was appointed Chief Operating Officer.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.

PureTech Health: Notice of Results

Retrieved on: 
星期四, 四月 18, 2024
Science, Other Science, Biotechnology, Research, General Health, Health, FDA, Clinical Trials, Account, PRTC, Annual report

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024.
  • A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations .

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Retrieved on: 
星期二, 四月 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Southern California, FDA, Idiopathic pulmonary fibrosis, University, Vital capacity, FVC, Safety, Survival, IPF, CNS, Incidence, Patient, TID, Pirfenidone, Caregiver, Aes, Central nervous system, PRTC, Biomarker, Pharmacology, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).
  • This PK profile and the resulting favorable tolerability have been demonstrated across multiple clinical trials in more than 400 individuals.
  • PureTech believes the results of the Phase 2b trial, together with an additional Phase 3 trial, could serve as the basis for registration in the U.S. and other geographies.
  • PureTech would like to extend its gratitude to those participating in the ELEVATE IPF trial, especially the people living with IPF and their caregivers, the clinical trial sites, investigators and advocacy groups.

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Retrieved on: 
星期四, 四月 11, 2024
Oncology, Health, FDA, Clinical Trials, Research, Science, Biotechnology, Cancer, Fast Track, Venetoclax, Food, Prognosis, Survival, AML, Bone marrow, Patient, Tislelizumab, Acute myeloid leukemia, PRTC, Head, Clinical trial, BeiGene, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas (“head and neck cancers”).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas (“head and neck cancers”).
  • It is being evaluated in two ongoing clinical trials:
    a Phase 1/2 adaptive design trial in advanced/metastatic solid tumors, including head and neck cancers.
  • “By granting Fast Track designation to LYT-200 for head and neck cancers, the FDA continues to highlight areas of critical need within oncology as well as the potential for LYT-200,” said Aleksandra Filipovic, M.D., Ph.D., Head of Oncology at PureTech.
  • The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML .

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
星期二, 四月 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.